MHRA warns Ozempic/Wegovy could cause rare eye condition

Britain's MHRA has warned that the diabetes/weight‑loss injections Ozempic (semaglutide) and Wegovy may cause a rare optic nerve condition (NAION) that can lead to sudden vision loss in one eye. The regulator has received three reports, but says the overall risk is very small; with about two million UK users, patients and clinicians are advised to be alert to symptoms and seek urgent eye care if vision changes occur. The warning also notes that pancreatitis is a known but infrequent side effect of GLP-1 weight‑loss drugs.